Creative Planning’s Repros Therapeutics Inc. RPRX Stock Holding History

Creative Planning’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,000	Closed	-$2K	–	4766
2017 Q2	$2K	Sell	5,000 -100	-2%	-$73	﹤0.01%	4395
2017 Q1	$6K	Hold	5,100	–	–	﹤0.01%	3927
2016 Q4	$7K	Buy	5,100 +100	+2%	+$174	﹤0.01%	3820
2016 Q3	$10K	Hold	5,000	–	–	﹤0.01%	3561
2016 Q2	$8K	Hold	5,000	–	–	﹤0.01%	3436
2016 Q1	$5K	Sell	5,000 -5,050	-50%	-$4.93K	﹤0.01%	3655
2015 Q4	$12K	Buy	10,050 +9,913	+7,236%	+$31.8K	﹤0.01%	3227
2015 Q3	$1K	Buy	+137	New	+$1.05K	﹤0.01%	4279
2015 Q2	–	Sell	-100	Closed	-$1K	–	4313
2015 Q1	$1K	Hold	100	–	–	﹤0.01%	4183
2014 Q4	$1K	Buy	100 +50	+100%	+$426	﹤0.01%	4124
2014 Q3	$0	Hold	50	–	–	﹤0.01%	4407
2014 Q2	$1K	Hold	50	–	–	﹤0.01%	3743
2014 Q1	$1K	Buy	+50	New	+$968	﹤0.01%	3607

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning's RPRX Position: Q3 2017 in Review

Creative Planning sold out of Repros Therapeutics Inc. (RPRX) in Q3 2017, closing a stake of 5,000 shares — an estimated $2K sold.

Creative Planning first reported a position in RPRX in Q1 2014 and held it in 13 quarters. The position peaked at $12K in Q4 2015. 28 funds tracked by Wall St. Rank hold RPRX as of Q3 2017.

Creative Planning reported no remaining Repros Therapeutics Inc. position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 5,000 Repros Therapeutics Inc. shares in Q3 2017, an estimated $2K.
Creative Planning first reported a position in Repros Therapeutics Inc. in Q1 2014 and held it in 13 quarters.
Creative Planning's Repros Therapeutics Inc. position peaked at $12K in Q4 2015.
28 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.